Genesis Therapeutics partners with NVIDIA to boost AI-driven drug discovery
Genesis also announced a further investment from NVentures, NVIDIA’s venture capital arm.
Markets & regulatory news
US companies enhancing decentralized clinical trials
Traditional clinical trials usually rely on several physical trial sites to recruit and monitor patients.
Medable and Google Cloud partner to deliver digital clinical trials technology
The partners will work together to make Medable’s digital and decentralized clinical trial platform available on Google Cloud Marketplace.
Gifthealth and United Digestive partner for enhanced GI care access
Gifthealth Partners with United Digestive to boost patient access and procedure prep.
Jennifer Visser-Rogers: Leading science transformation at Coronado Research
In a conversation with Professor Jennifer Visser-Rogers, chief scientific officer at Coronado Research, she shares insights on the evolving landscape of pharmaceutical development.
Private equity firms GHO and Ampersand acquire Avid Bioservices for $1.1 billion
Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the acquisition of Avid Bioservices.
Insights from Tjoapack’s CEO: 35 years of pharma packaging:
Celebrating 35 years of innovation, Tjoapack has evolved into a leading force in pharmaceutical packaging.
Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Streamlining eCOA: From complex setup to simplified solutions
As clinical trials evolve, electronic Clinical Outcome Assessments (eCOA) remain central to data quality but often lag in adoption due to complex setup and deployment challenges.
Starget Pharma’s AI-Driven Cancer Therapy Gains $5.1 Million Backing
Innovative radiotherapy offers a precision treatment alternative.
FDA grants accelerated approval to Novartis’ Scemblix as a first-line leukemia therapy
Scemblix is the first drug to show superiority over all standard of care therapies for a rare type of leukemia.
Top 10 rare disease pharma sees 10.4% rise in therapy start
A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% increase in therapy initiation, driven by AI-enabled patient outreach and personalized communications.
Axonis raises $115 million to overcome drug resistance in epilepsy
The Boston-based startup Axonis Therapeutics has bagged $115 million in a Series A round to fuel its pipeline of treatments for pain, epilepsy and other conditions.
Competitors race to launch GLP-1 drugs amid soaring weight loss demand
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their own versions of these highly coveted drugs.
GSK beefs up US manufacturing site with $800 million investment
The big pharma company GlaxoSmithKline will inject up to $800 million into its manufacturing site in Marietta, Pennsylvania, to double its size and capacity.
Rentschler Biopharma expands CDMO facilities in Germany
The expansion will involve the construction of a new buffer media facility and represents the largest investment from Rentschler at its Germany headquarters.
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of its cost-effectiveness.
PTC Therapeutics’ Translarna misses European regulatory hurdle again
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has once again snubbed Translarna (ataluren), PTC Therapeutics’ treatment for the genetic disease Duchenne muscular dystrophy (DMD).
Seaport Therapeutics closes $225 million Series B to develop neuropsychiatric drugs
The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major depressive disorder and generalized anxiety disorder.
Investors and big pharma no longer avoiding techbio companies
Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts at TechBio UK 2024, an event run by the BioIndustry Association (BIA).
Lundbeck acquires Longboard Pharmaceuticals in $2.6 billion deal
The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
Sanofi abandons phase 2 trial of Denali’s multiple sclerosis candidate
The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.
Women in Science: Sharmeen Roy - 'pharmacy is the perfect blend of all my favourite subjects'
At the forefront of precision dosing, Sharmeen leads DoseMe's efforts to transform personalized medicine from lab research to bedside application.
Evaxion’s AI-immunology platform shines in multiple clinical trials
Evaxion’s proprietary AI-Immunology platform has shown in clinical trials that it can select clinically relevant cancer vaccine targets.
Preparing for the US Biosecure Act - what does it mean for the pharma industry?
The US Biosecure Act was passed by the House of Representatives in September and seems likely to become law.
Drug discovery and bringing new medicine to market - the future of AI in pharma
Artificial intelligence (AI) is now infiltrating core industries and according to Forbes, the market is expected to reach a value of $22.6 billion dollars by next year (2025).
Small molecules in focus as Recipharm bolsters global production facilities
Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm is expanding its manufacturing capacity with undisclosed investments in its small molecule offerings.
Innovent and Ask Pharm join forces to commercialize third-generation lung cancer therapy
The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.
From CDMOs to artificial intelligence - what's the latest in the world of outsourcing?
Outsourcing Pharma sat down ahead of CPHI with Dr Andreas Raabe, CEO of Adragos Pharma, to explore the evolving world of pharmaceutical outsourcing.
LoQus23 Therapeutics raises £35m to advance therapy for Huntington’s disease
The proceeds of the financing will support the development of LoQus23’s lead candidate, a small molecule inhibitor that is expected to enter the clinic in 2026.
SK pharmteco to strengthen small molecule and peptide capacity with $260 million investment
SK Group’s contract development and manufacturing organization (CDMO) arm SK pharmteco is spending $260 million to expand its small molecule and peptide manufacturing muscle in South Korea.
Symbiosis expands sterile manufacturing with new facility and innovations
As CPHI Milan 2024 approaches, Symbiosis Pharmaceutical Services is gearing up to showcase major expansions and innovations in sterile biopharmaceutical manufacturing.
Quotient Sciences expands with mRNA Focus at CPHI 2024
During the show, Quotient Sciences CEO Thierry Van Nieuwenhove will share insights on how the company is adapting to new FDA regulations.
CPHI 2024
CBD-based formulations from dsm-firmenich at CPHI 2024
At this October’s CPHI event being held in Milan, dsm-firmenich, is inviting stakeholders across the pharmaceutical market to immerse themselves in its patient-inspired innovations.
Authenticx CPO Eric Prugh on the impact of AI technology in pharmacovigilance
Artificial intelligence has emerged as a potential solution to inconsistent reporting of adverse events, which to this day remains one of the main challenges in the field of pharmacovigilance.
Microbiome startup Sequentia Biotech heralds “new era” in omics with €10 million round
The Barcelona-based startup Sequentia Biotech has raised €10 million ($11 million) in a Series A round to finance the development of its omics-based technology for use in biomedicine, agritech and food.
Biohaven’s real-world trial shows positive results for spinocerebellar ataxia drug
The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will now file with the FDA.
NuraBio closes $140m fundraising to develop neuroprotective drugs
The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, shortly after successfully completing a first phase 1 clinical trial.
Boehringer Ingelheim score with phase 3 idiopathic pulmonary fibrosis win
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
F2G raises $100 million to combat innovation 'paucity' in antifungals
One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.
uMotif expands site and patient platform with ClinOne acquisition
uMotif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its platform with the acquisition of ClinOne, a provider of site platform solutions.
CluePoints sponsors RBQMLive 2024, focusing on risk-based quality management
CluePoints, the leading provider of risk-based quality management (RBQM) and data quality oversight software, has announced the full agenda and speaker line-up for the highly anticipated RBQMLive 2024.
Pharma companies must prioritize patient reach, report says
Pharmaceutical companies are under increasing pressure to ensure that essential healthcare products are accessible to all, regardless of socioeconomic status or location.
Creyon Bio secures second patent for AI-powered oligonucleotide engineering
Creyon Bio Inc., a clinical-stage biotechnology company specializing in AI and machine learning-enabled oligonucleotide-based medicines (OBMs), recently announced the issuance of its second US patent.
Reimagine Care and Memorial Hermann boost cancer care engagement
Reimagine Care, the leading provider of on-demand cancer care, and Memorial Hermann Health System, one of Texas's largest not-for-profit health systems, have announced an ambitious multi-year expansion of their pioneering partnership.
‘We’re here and we’re ready’ - Dalgety secures UK licence to supply medical cannabis
Dalgety, one of the UK's leading medical cannabis cultivators, has achieved a significant milestone by securing a Home Office licence to supply medical cannabis within the UK.
UCB advances innovation strategy with $680M divestment deal in China
UCB, a global biopharmaceutical leader, has taken a significant step in refining its strategic focus by divesting its mature neurology and allergy portfolio in China.
Nasal powder shows promise in boosting immune defense
The INNA-051 formulation is designed to enhance the body’s natural immune response, targeting individuals aged 60 and over who are at increased risk for complications from respiratory viral infections.
ALZpath and Beckman Coulter partner for breakthrough diagnostic
In the ongoing battle against Alzheimer’s disease, early diagnosis is crucial.
New XpressGT kit speeds up diagnosis of diabetes, endometriosis and liver disease
DirectSens, an Austrian biosensor developer, has launched its latest innovation, the XpressGT RUO kit, designed for the detection of conditions related to insulin resistance, including gestational diabetes (GDM), endometriosis, and liver disease.